Assessment of type I interferon response in routine practice in France in 2022
Eric Hachulla,
Isabelle Melki,
Brigitte Bader-Meunier,
Alexandre Belot,
Sophie Georgin-Lavialle,
Sébastien Viel,
Thierry Walzer,
Anais Nombel,
Anne Perrine Foray,
Lorna Garnier,
Christine Lombard
Affiliations
Eric Hachulla
Département de Médecine Interne et d`Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), Université de Lille, CHU Lille, Lille, France
Isabelle Melki
General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré Mother-Child University Hospital, AP-HP, Paris, France
Brigitte Bader-Meunier
Department of Paediatric Hematology-Immunology and Rheumatology, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Necker-Enfants Malades Hospital, AP-HP, Paris, France
Alexandre Belot
International Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France
Sophie Georgin-Lavialle
Service Médecine Interne, Centre de référence des maladies autoinflammatoires et des amyloses (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France
Sébastien Viel
Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Thierry Walzer
International Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France
Anais Nombel
Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Anne Perrine Foray
Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Lorna Garnier
Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Christine Lombard
Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type I interferon pathway assay that has been set up and used routinely since 2018 in Lyon, France.
